Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Last trade$6.60
Day change-$0.03 (-0.45%)
Day range$6.29 – $6.65
Volume382,644
Market cap$439M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$438.83M
Price / earnings
—
Price / book
-11.6×
Price / sales
1.35×
EV / sales
1.74×
EV / EBITDA
-112.82×
Profitability
Earnings per share
-$0.47
Return on assets
-10.96%
Return on equity
82.28%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-4.5×
Current ratio
1.42×
Quick ratio
0.84×
Cash ratio
0.29×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EOLS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$77.95M
$84.08M
$73.14M
$90.3M
$68.97M
$69.39M
$68.52M
$78.95M
Cost of revenue
$27.27M
$26.9M
$24.24M
$31.01M
$23.13M
$24.07M
$21.87M
$26.31M
Gross profit
$50.69M
$57.18M
$48.9M
$59.29M
$45.84M
$45.32M
$46.66M
$52.63M
Selling, general and administrative
$52.92M
$57.05M
$51.98M
$54.66M
$52.82M
$56.68M
$56.64M
$50.24M
Research and development
$3.02M
$1.89M
$2.24M
$3.48M
$2.05M
$1.84M
$2.21M
$2.43M
Total operating expenses
$59.11M
$60.47M
$55.75M
$55.07M
$57.34M
$59.44M
$61.83M
$54.95M
Operating income
-$8.43M
-$3.29M
-$6.85M
$4.22M
-$11.5M
-$14.12M
-$15.17M
-$2.31M
Interest expense
-$4.25M
-$4.17M
-$3.98M
-$3.98M
-$4.09M
-$7.21M
-$4.42M
-$4.57M
Income before taxes
-$12.23M
-$8.21M
-$10.42M
$515K
-$15.57M
-$17.09M
-$18.82M
-$6.35M
Income taxes
$285K
-$154K
$256K
$385K
$167K
$53K
$72K
$440K
Net income
-$12.52M
-$8.05M
-$10.67M
$130K
-$15.74M
-$17.14M
-$18.89M
-$6.79M
Net income attributable to common shareholders
-$12.52M
-$8.05M
-$10.67M
$130K
-$15.74M
-$17.14M
-$18.89M
-$6.79M
EBITDA
-$6.04M
-$957K
-$4.5M
$6.47M
-$8.11M
-$12.39M
-$13.61M
-$940K
Basic earnings per share
-$0.19
-$0.12
-$0.16
$0.00
-$0.24
-$0.27
-$0.30
-$0.11
Diluted earnings per share
-$0.19
-$0.12
-$0.16
$0.00
-$0.24
-$0.27
-$0.30
-$0.11
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating Evolus, Inc. for potential securities fraud following an FDA warning letter on October 2, 2026, that flagged misleading Instagram promotion of its wrinkle treatment Jeuveau. The FDA objected to false claims about the product's efficacy and safety information minimization. Evolus's stock fell 7.15% to $7.14 per share on the news.
Pomerantz LLP is investigating Evolus, Inc. for potential securities fraud following an FDA warning letter on October 2, 2026, that flagged misleading Instagram promotion of its wrinkle treatment Jeuveau. The FDA objected to false claims and minimization of safety information. Evolus's stock price fell 7.15% to $7.14 per share on the news.
Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.
AEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay results falling within equivalence criteria established from BOTOX® reference results.
Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.